New Israeli-led AI model to predict chemotherapy benefit in breast cancer

The Jerusalem Post highlights a groundbreaking advancement in cancer treatment developed by researchers at the Technion-Israel Institute of Technology. This new artificial intelligence model promises to revolutionize the approach to chemotherapy for breast cancer patients, particularly those with hormone receptor-positive, HER2-negative early-stage disease.

The core challenge addressed is identifying which patients will truly benefit from adjuvant chemotherapy after surgery. Currently, this decision is fraught with difficulty, as while chemotherapy can reduce recurrence risk, it often comes with significant side effects, and many patients do not benefit. This Israeli innovation offers a powerful solution by analyzing routine pathology slides, a method that is both faster and more accessible than current costly genomic tests.

“

These are complex biological signals that the human eye cannot consistently quantify.

This AI model, the first of its kind validated in a large clinical trial, analyzes subtle biological signals invisible to the human eye. Dr. Gil Shamai, who led the study, explains that the model integrates numerous cues to generate a score reflecting both recurrence risk and the likelihood of benefiting from chemotherapy. Presented to an enthusiastic audience at the European Society for Medical Oncology conference, this development underscores Israel's leading role in medical innovation and its commitment to improving patient outcomes globally.

“

The model integrates many subtle cues to generate a score that reflects both recurrence risk and expected benefit from chemotherapy.